Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

February 14, 2024

Study Completion Date

February 14, 2024

Conditions
Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRichter SyndromeSmall Lymphocytic LymphomaTransformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell LymphomaTransformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaTransformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Duvelisib

Given PO

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

David Bond, MD

OTHER